Cargando…

Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab

The purpose of the study is to explore the morphofunctional fluctuations in eyes treated for neovascular AMD (nAMD) when treatment is switched from aflibercept or ranibizumab to brolucizumab. A total of 31 eyes of 31 patients with nAMD with type 1 macular neovascularization (MNV) were included. All...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viggiano, Pasquale, Grassi, Maria Oliva, Boscia, Giacomo, Pignataro, Mariagrazia, Petruzzella, Giovanni, Borrelli, Enrico, Molfetta, Teresa, Alessio, Giovanni, Boscia, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570643/ https://www.ncbi.nlm.nih.gov/pubmed/36233385 http://dx.doi.org/10.3390/jcm11195517

Ejemplares similares

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Effects of diabetic retinopathy on longitudinal morphological changes in AMD-associated type 1 macular neovascularization
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
por: Boscia, Giacomo, et al.
Publicado: (2023)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
por: Khoramnia, Ramin, et al.
Publicado: (2021)

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
por: Pearce, Ian, et al.
Publicado: (2022)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting
por: Rübsam, Anne, et al.
Publicado: (2022)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Biofeedback Training after Successful Inverted Internal Limiting Membrane (ILM)-Flap Technique for High Myopic Macular Hole
por: Sborgia, Alessandra, et al.
Publicado: (2023)

Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
por: Chakraborty, Somnath, et al.
Publicado: (2022)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
por: Chuan, Junlan, et al.
Publicado: (2022)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Intravitreal Injections in Arc Sterile Setting: Safety Profile after More Than 10,000 Treatments
por: Furino, Claudio, et al.
Publicado: (2020)

Impact of Bleaching on Photoreceptors in Different Intermediate AMD Phenotypes
por: Borrelli, Enrico, et al.
Publicado: (2019)

How Reliable Is Pyramidal Wavefront-Based Sensor Aberrometry in Measuring the In Vivo Optical Behaviour of Multifocal IOLs?
por: D’Oria, Francesco, et al.
Publicado: (2023)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
por: Bilgic, Alper, et al.
Publicado: (2021)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Therapy for Diabetic Macular Edema: An Update
por: Furino, Claudio, et al.
Publicado: (2021)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

One-year outcomes of 27-gauge versus 25-gauge pars plana vitrectomy for uncomplicated rhegmatogenous retinal detachment repair
por: Sborgia, Giancarlo, et al.
Publicado: (2019)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic
por: Borrelli, Enrico, et al.
Publicado: (2020)

Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema
por: Furino, Claudio, et al.
Publicado: (2017)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
por: Gigon, Anthony, et al.
Publicado: (2022)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Efficacy of Intravitreal Dexamethasone Implant in Different Patterns of Diabetic Macular Edema
por: Furino, Claudio, et al.
Publicado: (2020)

Citrobacter koseri: A Cause of Silicone Oil Related Endophthalmitis after Post Pars Plana Vitrectomy
por: Sborgia, Luigi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b6r5mnaopbin2bchp2jutrfrm1